Prenatal and New-born Genetic Testing Market Key Growth Analysis – Berry Genomics, BGI, Biorad, Illumina, Laboratory Corporation of America, Natera, Qiagen, Sequenom, Trivitron Healthcare and Verinata health

This 2018 Prenatal and New-born Genetic Testing market report provides 2024 forecasts built using statistical analysis while covering data from primary research as well as secondary sources that help gain market insights and provide industry growth expectations.

Prenatal and New-born Genetic Testing Market will exceed USD 7 billion by 2024, U.S. dominated the market in 2017 owing to ongoing technological advancements along with favorable reimbursement policies. The U.S. region had 99% of newborn screening rate and high awareness about prenatal and new-born genetic testing will be responsible for the market growth in U.S. Presence of technologically advanced and equipped manufacturing companies along with government initiatives supporting screening activities that will impel market growth.

Report Mainly focuses on the top Manufacturers in global market are given bellow

Ariosa Diagnostics (Roche), Berry Genomics, BGI, Biorad, Illumina, Laboratory Corporation of America, Natera, Qiagen, Sequenom, Trivitron Healthcare and Verinata health.

Request a Sample of this premium Research [email protected]

By Technology

  • Screening {Chorionic Villus Sampling, Maternal Serum Screening, Amniocentesis, Non-invasive prenatal testing}, Diagnostic {mmPCR, Spectrophotometer, FISH, Assays

By Disease

  • Downs Syndrome
  • Phenylketonuria
  • Cystic Fibrosis

Sickle Cell Anaemia

By End-use

  • Hospitals
  • Maternity & Specialty Clinics
  • Diagnostic Centres

Increasing prevalence of birth defects among the European population is one of the major reason for rising infant mortality. The necessary government initiatives in order to conduct prenatal and new-born genetic tests to diagnose the birth defects will increase the number of infant screening programs giving rise to market growth opportunities.

However, lack of infrastructure and skilled labor in the low and middle income countries will impede the parental and newborn genetic testing market growth. Moreover, ethical issues associated with prenatal and newborn testing coupled with incidences of false test results will  further hamper industry growth.

Screening technology holds majority of market share in the year 2017 owing to increasing number of screening procedures of pregnant women while delivery. The rise in awareness among the families regarding genetic birth defects and early detection of genetic disorder will augment the segment growth in the near future.

Downs Syndrome recorded largest market share in the prenatal and newborn genetic testing market due to increasing in number of births diagnosed with Downs syndrome. The rise in incidences of women getting married at later stage of life is leading to increasing births with Downs Syndrome. These factors will further support the segment growth over the forecast timeframe.

Hospitals hold the majority of market share owing to increasing number of births in hospitals. Hospitals are aided by the government and provide the facilities require for the newborn screening. The increase in number of screening programs in hospitals provides significant scope for the market growth.


Request a Discount on standard prices of this premium Prenatal and New-born Genetic Testing Market Research [email protected]


The above information is provided on a regional and country basis for the following:

  • North America (U.S., Canada)
  • Europe (Germany, UK, France, Italy, Spain)
  • Asia Pacific (China, India, Japan, Australia)
  • Latin America (Brazil, Mexico, Argentina)
  • MEA (Saudi Arabia, South Africa)

Technological advancement and several benefits associated with infant genetic testing will be major driver of the prenatal and new-born genetic testing market. Introduction of prenatal testing has led to substantial amount of increase in adoption rate of new testing technologies such as non-invasive prenatal testing (NIPT) for detection of sub chromosomal abnormalities, single-gene disorders and aneuploidy in North America region. Inclination towards minimally invasive infant genetic testing along with demand for early detection of birth defects will one of the major reason for market growth.

To View Full [email protected]

About Us: allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

Contact Us:

Market Study Report

4 North Main Street,

Selbyville, Delaware 19975


Phone: 1-302-273-0910

US Toll Free: 1-866-764-2150

Email:[email protected]



Posted by on Saturday September 22 2018, 10:00 AM EDT. All trademarks acknowledged. Filed under Biotechnology, Business & Financial Services, Business Services, Diagnostics, Featured Press Release, Healthcare, Life Sciences, Manufacturing, Medical Devices, Pharmaceuticals. Comments and Trackbacks closed. Follow responses: RSS 2.0

Comments are closed

News Categories

Featured Press Releases

Log in